Ginger, valerian, comfrey "informational" monographs published by USP.
This article was originally published in The Tan Sheet
Executive Summary
GINGER FOR NAUSEA, VOMITING REQUIRES FURTHER STUDY before the plant can be recommended for use in humans, the U.S. Pharmacopeia states in an "informational" monograph released in January. Upon considering available literature on ginger, USP advisory panels suggest future research, "including at least one adequate and well-controlled clinical trial," be conducted to examine the botanical's reported uses for the treatment and prevention of nausea and vomiting related to motion sickness. The monograph is published in the monthly update to the USP DI compendium of drug, nutritional and therapeutic information.
You may also be interested in...
USP Negative Ephedra Monograph To Follow FDA Final Action
The United States Pharmacopeia plans to create a negative monograph for ephedra following FDA action on the dietary supplement ingredient, CEO Jerome Halperin said at a meeting of the USP Ad Hoc Panel on Botanicals in Rockville, Md. Nov. 8.
USP Negative Ephedra Monograph To Follow FDA Final Action
The United States Pharmacopeia plans to create a negative monograph for ephedra following FDA action on the dietary supplement ingredient, CEO Jerome Halperin said at a meeting of the USP Ad Hoc Panel on Botanicals in Rockville, Md. Nov. 8.
USP Negative Ephedra Monograph To Follow FDA Final Action
The United States Pharmacopeia plans to create a negative monograph for ephedra following FDA action on the dietary supplement ingredient, CEO Jerome Halperin said at a meeting of the USP Ad Hoc Panel on Botanicals in Rockville, Md. Nov. 8.